{"id":3098,"date":"2019-12-17T16:50:00","date_gmt":"2019-12-17T16:50:00","guid":{"rendered":"https:\/\/cdafound.org\/?p=3098"},"modified":"2025-01-14T22:16:59","modified_gmt":"2025-01-14T22:16:59","slug":"nonalcoholic-fatty-liver-disease-burden-switzerland-2018-2030","status":"publish","type":"post","link":"https:\/\/cdafound.org\/fr\/nonalcoholic-fatty-liver-disease-burden-switzerland-2018-2030\/","title":{"rendered":"Fardeau de la st\u00e9atose h\u00e9patique non alcoolique - Suisse 2018-2030"},"content":{"rendered":"<h2 class=\"wp-block-heading\">R\u00e9sum\u00e9<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">En raison des niveaux \u00e9pid\u00e9miques d&#039;ob\u00e9sit\u00e9 et de diab\u00e8te sucr\u00e9, la st\u00e9atose h\u00e9patique non alcoolique (NAFLD) et la st\u00e9atoh\u00e9patite non alcoolique (NASH) contribueront \u00e0 l&#039;augmentation du fardeau des maladies h\u00e9patiques en Suisse. Un mod\u00e8le de Markov a \u00e9t\u00e9 construit pour quantifier la progression de la fibrose parmi les populations NAFLD et NASH, et pr\u00e9dire la charge de morbidit\u00e9 jusqu&#039;en 2030. La tendance \u00e0 long terme de la pr\u00e9valence de la NAFLD \u00e9tait bas\u00e9e sur les changements dans la pr\u00e9valence de l&#039;ob\u00e9sit\u00e9 chez les adultes. Les estimations publi\u00e9es et les donn\u00e9es de surveillance ont \u00e9t\u00e9 appliqu\u00e9es pour construire et valider les projections du mod\u00e8le. La pr\u00e9valence de la NAFLD a augment\u00e9 jusqu&#039;en 2030 parall\u00e8lement aux augmentations projet\u00e9es de l&#039;ob\u00e9sit\u00e9 chez les adultes. En 2030, il y avait environ 2 234 000 (1 918 000\u20132 553 000) cas de NAFLD, soit 24,3% (20,9\u201327,8%) de la population suisse totale (tous \u00e2ges). Les augmentations des cas de NASH \u00e9taient relativement plus importantes que les cas de NAFLD. Les cas incidents de maladie h\u00e9patique avanc\u00e9e devraient augmenter d&#039;environ 401 TTP1T d&#039;ici 2030, et les d\u00e9c\u00e8s accidentels du foie dus \u00e0 la NAFLD passeront de 580 d\u00e9c\u00e8s en 2018 \u00e0 820 d\u00e9c\u00e8s en 2030. nombre de cas de maladie h\u00e9patique avanc\u00e9e et mortalit\u00e9 li\u00e9e \u00e0 la NAFLD et \u00e0 la NASH. Le ralentissement de la croissance de l&#039;ob\u00e9sit\u00e9 et du syndrome m\u00e9tabolique, ainsi que des th\u00e9rapies potentielles futures, sont n\u00e9cessaires pour r\u00e9duire le fardeau des maladies h\u00e9patiques.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Des pays:<\/strong> la Suisse<\/p>\n\n\n\n<div class=\"wp-block-buttons is-content-justification-center is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button is-style-outline is-style-outline--1\"><a class=\"wp-block-button__link has-text-color wp-element-button\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/31846507\/\" style=\"border-radius:6px;color:#951b23\" target=\"_blank\" rel=\"noreferrer noopener\">Lire le rapport complet<\/a><\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Summary As a result of epidemic levels of obesity and diabetes mellitus, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) will contribute to increases in the liver-related disease burden in Switzerland. A Markov model was built to quantify fibrosis progression among the NAFLD and NASH populations, and predict disease burden up to 2030. Long-term [&hellip;]<\/p>\n","protected":false},"author":24,"featured_media":3113,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[9],"tags":[24],"publication-author":[747,750,528,535,748,746,749,745,751,522,494,530],"class_list":["post-3098","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-publication","tag-nafld","publication-author-bellentani-s","publication-author-cerny-a","publication-author-dufour-jf","publication-author-estes-c","publication-author-goossens-n","publication-author-jornayvaz-fr","publication-author-mertens-j","publication-author-moriggia-a","publication-author-muellhaupt-b","publication-author-negro-f","publication-author-razavi-h","publication-author-semela-d"],"acf":[],"_links":{"self":[{"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/posts\/3098","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/users\/24"}],"replies":[{"embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/comments?post=3098"}],"version-history":[{"count":5,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/posts\/3098\/revisions"}],"predecessor-version":[{"id":7487,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/posts\/3098\/revisions\/7487"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/media\/3113"}],"wp:attachment":[{"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/media?parent=3098"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/categories?post=3098"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/tags?post=3098"},{"taxonomy":"publication-author","embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/publication-author?post=3098"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}